Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Myeloproliferative Disorders × cabozantinib × 30 days × Clear all

Sponsor

Conditions

Carcinoma, Renal Cell 14 Urinary Bladder Neoplasms 3 Urethral Neoplasms 3 Osteosarcoma 3 Melanoma 3 Clear-cell metastatic renal cell carcinoma 3 Urogenital Neoplasms 2 Ureteral Neoplasms 2 Small Cell Lung Carcinoma 2 Sarcoma, Ewing 2 Prostatic Neoplasms 2 Penile Neoplasms 2 Neuroendocrine Tumors 2 Kidney Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Hepatocellular 2 Carcinoma 2 Brain Neoplasms 2 Adrenocortical Carcinoma 2 Urachal adenocarcinoma 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Kaposi 1 Refractory Differentiated Thyroid Gland Carcinoma 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Non functioning pancreatic endocrine tumor 1 Neurofibromatosis 1 1 Neurofibroma, Plexiform 1 Neoplasm Metastasis 1

Interventions

Specimen Handling 8 Biopsy 8 fludarabine 6 Azacitidine 6 venetoclax 5 Whole-Body Irradiation 4 Busulfan 4 ruxolitinib 3 decitabine and cedazuridine drug combination 3 Injections 3 Cytarabine 3 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3 fludarabine phosphate 2 Tacrolimus 2 Stem Cell Transplantation 2 Mycophenolic Acid 2 Liposomes 2 Granulocyte Colony-Stimulating Factor 2 Daunorubicin 2 Cyclosporins 2 Cyclophosphamide 2 CPX-351 2 ponatinib 1 pevonedistat 1 peginterferon alfa-2b 1 onvansertib 1 olutasidenib 1 nilotinib 1 luspatercept 1 ivosidenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡